Helen Frankenthaler Foundation

Neurotransmitter release inhibitor peptide

Neurotensin Modulates the Electrical Activity of Frog Pituitary Melanotropes via Activation of a G-Protein-Coupled Receptor Pharmacologically Related to Both the NTS1 and nts2 Receptors of Mammals

Abstract

The primary structure of frog neurotensin (f NT) has recently been determined and it has been shown that f NT is a potent stimulator of α-MSH secretion by frog pituitary melanotropes. In the present study, we have investigated the effects of f NT on the electrical activity of cultured frog melanotropes by using the patch-clamp technique and we have determined the pharmacological profile of the receptors mediating the effect of f NT. In the cell-attached configuration, f NT (10–7 M) provoked an increase in the action current discharge followed by an arrest of spike firing. In the gramicidin-perforated patch configuration, f NT (10–7 M) induced a depolarization accompanied by an increase in action potential frequency and a decrease in membrane resistance. Administration of graded concentrations (10–10 to 10–6 M) of f NT or the C-terminal hexapeptide NT(8–13) caused a dose-dependent increase in the frequency of action potentials with EC 50 of 2 × 10–8 and 5 × 10–9 M, respectively. The stimulatory effect of f NT was mimicked by various pseudopeptide analogs, with the following order of potency: Boc-[Trp 11]NT(8–13) > Boc-[D-Trp 11]NT(8–13) > Boc-[Lys 8,9, Nal 11]NT(8–13) > Boc-[Ψ11,12]NT(8–13). In contrast, the cyclic pseudopeptide analogs of NT(8–13), Lys-Lys-Pro-D-Trp-Ile-Leu and Lys-Lys-Pro-D-Trp-Glu-Leu-OH, did not affect the electrical activity. The NTS1 receptor antagonist and nts2 receptor agonist SR 48692 (10–5 M) stimulated the spike discharge but did not block the response to f NT. In contrast, SR 142948A (10–5 M), another NTS1 receptor antagonist and nts2 receptor agonist, inhibited the excitatory effect of f NT. The specific nts2 receptor ligand levocabastine (10–6 M) had no effect on the basal electrical activity and the response of melanotropes to f NT. In cells which were dialyzed with guanosine-5′-O-(3-thiotriphosphate) (10–4 M), f NT caused an irreversible stimulation of the action potential discharge. Conversely, dialysis of melanotropes with guanosine-5′-O-(2-thiodiphosphate) (10–4 M) completely blocked the effect of f NT. Pretreatment of cells with cholera toxin (1 µg/ml) or pertussis toxin (0.2 µg/ml) did not affect the electrical response to f NT. Intracellular application of the G o/i/s protein antagonist GPAnt-1 (3 × 10–5 M) had no effect on the f NT-evoked stimulation. In contrast, dialysis of melanotropes with the G q/11 protein antagonist GPAnt-2A (3 × 10–5 M) abrogated the response to f NT. The present data demonstrate that f NT is a potent stimulator of the electrical activity of frog pituitary melanotropes. These results also reveal that the electrophysiological response evoked by f NT can be accounted for by activation of a G q/11-protein-coupled receptor subtype whose pharmacological profile shares similarities with those of mammalian NTS1 and nts2 receptors.

References

  • Carraway R, Leeman SE: The isolation of new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem 1973;248:6854–6861.
  • Hammer RA, Leeman SE, Carraway R, Williams RH: Isolation of human intestinal neurotensin. J Biol Chem 1980;255:2476–2480.
  • Rostène WH, Alexander MJ: Neurotensin and neuroendocrine regulation. Front Neuroendocrinol 1997;18:115–173.
  • Desrues L, Tonon MC, Leprince J, Vaudry H, Conlon JM: Isolation, primary structure, and effects on α-melanocyte-stimulating hormone release of frog neurotensin. Endocrinology 1998;139:4140–4146.
  • Vincent JP, Mazella J, Kitabgi P: Neurotensin and neurotensin receptors. Trends Pharmacol Sci 1999;20:302–309.
  • Tanaka K, Masu M, Nakanishi S: Structure and functional expression of the cloned rat neurotensin receptor. Neuron 1990;4:847–854.
  • Vita N, Laurent P, Lefort S, Chalon P, Dumont X, Kaghad M, Gully D, Le Fur G, Ferrara P, Caput D: Cloning and expression of complementary DNA encoding a high affinity human neurotensin receptor. FEBS Lett 1993;317:139–142.
  • Mazella J, Botto JM, Guillemare E, Coppola T, Sarret P, Vincent JP: Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain. J Neurosci 1996;16:5613–5620.
  • Chalon P, Vita N, Kaghad M, Guillemot M, Bonnin J, Delpech B, Le Fur G, Ferrara P, Caput D: Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett 1996;386:91–94.
  • Vita N, Oury-Donat F, Chalon P, Guillemot M, Kaghad M, Bachy A, Thurneyssen O, Garcia S, Poinot-Chazel C, Casellas P, Keane P, Le Fur G, Maffrand JP, Soubrie P, Caput D, Ferrara P: Neurotensin is an antagonist of human neurotensin NT 2 receptor expressed in Chinese hamster ovary cells. Eur J Pharmacol 1998;360:265–272.
  • Mazella J, Zsürger N, Navarro V, Chabry J, Kaghad M, Caput D, Ferrara P, Vita N, Gully D, Maffrand JP, Vincent JP: The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor. J Biol Chem 1998;273:26273–26276.
  • Gully D, Canton M, Boigegrain R, Jeanjean F, Molimard JC, Poncelet M, Gueudet C, Heaulme M, Leyris R, Brouard A, Pelaprat D, Labbé-Jullié C, Mazella J, Soubrié P, Maffrand JP, Rostène W, Kitabgi P, Le Fur G: Biochemical and pharmalogical profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc Natl Acad Sci USA 1993;90:65–69.
  • Chabry J, Labbé-Jullié C, Gully D, Kitabgi P, Vincent JP, Mazella J: Stable expression of the cloned rat brain neurotensin receptor into fibroblasts: Binding properties, photoaffinity labeling, transduction mechanisms, and internalization. J Neurochem 1994;63:19–27.
  • Gully D, Labeeuw B, Boigegrain R, Oury-Donat F, Bachy A, Poncelet M, Steinberg R, Suaud-Chagny MF, Santucci V, Vita N, Pecceu F, Labbé-Jullié C, Kitabgi P, Soubrié P, Le Fur G, Maffrand JP: Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J Pharmacol Exp Ther 1997;280:802–812.
  • Choi SY, Chae HD, Park TJ, Ha H, Kim KT: Characterization of high affinity neurotensin receptor NTR1 in HL-60 cells and its downregulation during granulocytic differentiation. Br J Pharmacol 1999;126:1050–1056.
  • Yamada M, Yamada M, Lombet A, Forgez P, Rostène W: Distinct functional characteristics of levocabastine sensitive rat neurotensin NT 2 receptor expressed in Chinese hamster ovary cells. Life Sci 1998;62:375–380.
  • Botto JM, Guillemare E, Vincent JP, Mazella J: Effect of SR 48692 on neurotensin-induced calcium-activated chloride currents in the Xenopus oocyte expression system: Agonist-like activity on the levocabastine-sensitive neurotensin receptor and absence of antagonist effect on the levocabastine insensitive neurotensin receptor. Neurosci Lett 1997;223:193–196.
  • Labbé-Jullié C, Dubuc I, Brouard A, Doulut S, Bourdel E, Pelaprat D, Mazella J, Martinez J, Rostène W, Costentin J, Kitabgi P: In vivo and in vitro structure-activity studies with peptide and pseudopeptide neurotensin analogs suggest the existence of distinct central neurotensin receptor subtypes. J Pharmacol Exp Ther 1994;268:328–336.
  • Dubuc I, Sarret P, Labbé-Jullié C, Botto JM, Honoré E, Bourdel E, Martinez J, Costentin J, Vincent JP, Kitabgi P, Mazella J: Identification of the receptor subtype involved in the analgesic effect of neurotensin. J Neurosci 1999;19:503–510.
  • Jiang ZG, Pessia M, North RA: Neurotensin excitation of rat ventral tegmental neurones. J Physiol (Lond) 1994;474:119–129.
  • Kirkpatrick K, Bourque CW: Effects of neurotensin on rat supraoptic nucleus neurones in vitro. J Physiol (Lond) 1995;482:373–381.
  • Jassar BS, Harris KH, Ostashewski PM, Jhamandas JH: Ionic mechanisms of action of neurotensin in acutely dissociated neurons from the diagonal band of Broca of the rat. J Neurophysiol 1999;81:234–246.
  • Ibata Y, Kawakami F, Fukui K, Obata-Tsuto HL, Tanaka M, Kubo T, Okamura H, Morimoto N, Yanaihara C, Yanaihara N: Light and electron microscopic immunocytochemistry of neurotensin-like immunoreactive neurons in the rat hypothalamus. Brain Res 1984;302:221–230.
  • Goedert M, Lightman SL, Mantyh PW, Hunt SP, Emson PC: Neurotensin-like immunoreactivity and neurotensin receptors in the rat hypothalamus and in the neurointermediate lobe of the pituitary gland. Brain Res 1985;358:59–69.
  • Bello AR, Dubourg P, Kah O, Tramu G: Identification of neurotensin-immunoreactive cells in the anterior pituitary of normal and castrated rats. Neuroendocrinology 1992;55:714–723.
  • Sheppard MC, Askew RD, Shennan KIJ, Franks S, Ramsden DB: Neurotensin regulation of TSH secretion in the rat. Biochem Biophys Res Commun 1983;113:248–254.
  • Memo M, Castelletti L, Valerio A, Missale C, Spano PF: Identification of neurotensin receptors associated with calcium channels and prolactin release in rat pituitary. J Neurochem 1986;47:1682–1688.
  • Billiard J: Functional heterogeneity of pituitary gonadotropes in response to a variety of neuromodulators. Mol Cell Endocrinol 1996;123:163–170.
  • Jenks BG, Leenders HJ, Martens GJM, Roubos EW: Adaptation physiology: The functioning of pituitary melanotrope cells during background adaptation of the amphibian Xenopus laevis. Zool Sci 1993;10:1–11.
  • Roubos EW: Background adaptation by Xenopus laevis: A model for studying neuronal information processing in the pituitary pars intermedia. Comp Biochem Physiol 1997;118A:533–550.
  • Louiset E, Cazin L, Lamacz M, Tonon MC, Vaudry H: Dual effects of thyrotrophin-releasing hormone (TRH) on K+ conductance in frog pituitary melanotrophs. TRH-induced α-melanocyte-stimulating hormone release is not mediated through voltage-sensitive K+ channels. J Mol Endocrinol 1989;3:207–218.
  • Louiset E, Cazin L, Duval O, Lamacz M, Tonon MC, Vaudry H: Effect of acetylcholine on the electrical and secretory activities of frog pituitary melanotrophs. Brain Res 1990;533:300–308.
  • Louiset E, McKernan R, Sieghart W, Vaudry H: Subunit composition and pharmacological characterization of γ-aminobutyric acid type A receptors in frog pituitary melanotrophs. Endocrinology 2000;141:1083–1092.
  • Doulut S, Rodriguez M, Lugrin D, Vecchini F, Kitabgi P, Aumelas A, Martinez J: Reduced peptide bond pseudopeptide analogues of neurotensin. Peptide Res 1992;5:30–38.
  • Galas L, Lamacz M, Garnier M, Roubos EW, Tonon MC, Vaudry H: Involvement of protein kinase C and protein tyrosine kinase in thyrotropin-releasing hormone-induced stimulation of α-melanocyte-stimulating hormone secretion in frog melanotrope cells. Endocrinology 1999;140:3264–3272.
  • Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ: Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflügers Arch 1981;391:85–100.
  • Abe Y, Furukawa K, Itoyama Y, Akaike N: Glycine response in acutely dissociated ventromedial hypothalamic neuron of the rat: New approach with gramicidin perforated patch-clamp technique. J Neurophysiol 1994;72:1530–1537.
  • Mukai H, Munekata E, Higashijima T: G protein antagonists: A novel hydrophobic peptide competes with receptor for G protein binding. J Biol Chem 1992;15:16237–16243.
  • Tsunoda Y, Owyang C: The regulatory site of functional GTP binding protein coupled to the high affinity cholecystokinin receptor and phospholipase A 2 pathway is on the G β subunit of G q protein in pancreatic acini. Biochem Biophys Res Commun 1995;211:648–655.
  • Yajima Y, Uchino K, Ito H, Kawashima S: Mastoparan-stimulated prolactin secretion in rat pituitary GH 3 cells involves activation of G q/11 proteins. Endocrinology 1997;138:1949–1958.
  • Lopez Ordieres MG, Rodriguez de Lores Arnaiz G: Effect of neurotensin on synaptosomal membrane ATPase and p-NPPase activities. Ann NY Acad Sci 1997;834:548–551.
  • Cusack B, Chou T, Jansen K, McCormick DJ,